A Phase 4 interventional study of Everolimus (RAD001) in Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing everolimus in Neuroendocrine Tumors — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neuroendocrine Tumors.
Among the 22 studies testing everolimus in Neuroendocrine Tumors, this one is the 2nd largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 4, and was the 12th registered.
543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →1 of the 22 studies testing everolimus in Neuroendocrine Tumors is open now, in 1 country. Recruiting first, the newest first:
AC Camargo Cancer Center · Sites in Brazil
Ages 16+
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 41 across 387 interventional studies indexed under Neuroendocrine Tumors.
Median enrollment 38 across the 22 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
18 studies in Neuroendocrine Tumors by Novartis: none open now, 1 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 18 studies in Neuroendocrine Tumors by Novartis, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2011, is one of 4 in phase 4, and was the 10th registered.
Novartis’s Neuroendocrine Tumors studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing everolimus in Neuroendocrine Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 18 in Neuroendocrine Tumors:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This record combines the results of CRAD001K24133 and CRAD001K24133E1. The purpose of the CRAD001K24133 study was to evaluate the safety profile of everolimus in patients with advanced neuroendocrine tumors of pancreatic origin (pNETs) and to provide access of everolimus to this patient population. Everolimus was taken by participants until disease progression, unacceptable toxicity, death, discontinuation from the trial for any other reason, or when it became commercially available for this indication, or until May 30, 2012, whichever came first. Prior to amendment 1, the study enrolled participants with NET of the lung (L-NETs) and gastrointestinal (GI) (GI-NETs) origin. The core study was stopped (per protocol) because everolimus was approved for pNETs. All ongoing patients with pNETs were switched to commercially available everolimus. For GI and lung NETs, everolimus was not approved at the time the core study was stopped. Therefore, patients with GI or lung NETs were not able to switch to commercial drug. To provide study medication access to these patients beyond 30 May 2012, the open label extension study, CRAD001K24133E1, was conducted. In the extension study, RAD001K24133E1, participants with GI or lung NETs who had not progressed during therapy with everolimus in the core study and who had not suffered from intolerable toxicity, were enrolled and treated with everolimus in order to provide data on long-term safety and efficacy. Patients were treated until it became commercially available in the respective indication or until documented tumor progression, unacceptable toxicity, any other reason or until study end on 31 May 2017, whichever came first.
Core Inclusion:
Core Exclusion:
Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction
≤ 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia
Extension Inclusion and Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
Drug: Everolimus (RAD001)
Everolimus was supplied as tablets of 5mg strength.
Also known as: Afinitor
Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core)
The number of participants with AEs, SAEs and deaths were assessed.
Time frame: from the day of first treatment up to 19 months
Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths During the Extension Phase (E1)
The number of participants with AEs, SAEs and deaths were assessed.
Time frame: from the first day of treatment in the extension up to 4 years
Investigator-assessed Progression Free Survival (PFS) (Core)
PFS was defined as the time from the date of the first dose to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the study end date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last tumor assessment before the end of study date. Progression was defined,using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: from the day of first treatment up to 19 months
Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score (Core)
The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.
Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Mean EORTC QLQ-G.I. NET21 Score (Core)
The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions and disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening.
Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Number and Percentage of Participants With Ratings of 'no Problem, 'Some Problem' and 'Extreme Problem' in the EuroQol Five Dimensions Questionnaire (EQ-5D) (Core)
The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.
Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Mean EQ-5D Visual Analogue Scale (VAS) Score (Core)
The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.
Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Investigator-assessed Best Overall Response (Core)
Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: from the start of treatment, every 12 weeks for the first year and then every 6 months up to 19 months
Investigator-assessed Progression Free Survival (PFS) (E1)
PFS was defined as the time from the date of the start of therapy in the extension study to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the analysis cut-off date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last adequate tumor evaluation before the cut-off date or the anti-neoplastic therapy start date.
Time frame: from first date of treatment in the extension up to 4 years
Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)
The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status and QOL scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status and QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, changes are calculated as value at later time point minus value at baseline, and final scores are transformed such that they range from 0-100, where higher scores indicate better outcomes. A positive change from baseline indicates improvement.
Time frame: baseline, every 12 weeks and up to 4 years
Change in EORTC QLQ-G.I. NET21 Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)
The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions, disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening outcomes. A positive change from baseline indicates worsening.
Time frame: baseline, every 12 weeks and up to 4 years
Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)
The EQ-5D contains 2 sections:1st section has 1 item addressing each of 5 dimensions (mobility, self-care, usual activity, pain/discomfort, anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems, 1-3, respectively. A health state is defined by combining 1 level from each dimension. 243 health states are possible. Each state is referred to in a 5 digit code. E.g., state 11111 indicates no problems on any dimension, while state 11223 indicates no problems with mobility and self-care, some problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression. The 2nd section measures self-rated health status using a visual analogue scale (VAS) where 100 represents best possible health and 0 represents worst possible health. Patients are asked to rate their current health by placing a mark on the VAS. Scores from each section are then transformed into an overall score of 0 or 1, with 0= higher level of dysfunction.
Time frame: baseline, every 12 weeks and up to 4 years
Investigator-assessed Best Overall Response During the Extension Phase (E1)
Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: from the start of treatment, every 12 weeks for the first year and then every 6 months up to 4 years
| Milestone | pNET (Core) | Non-pNET (Core) | Lung NET (E1) | GI NET (E1) |
|---|---|---|---|---|
| Started | 126 | 120 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 126 | 120 | 0 | 0 |
| Withdrew: Patients completed per protocol | 85 | 44 | 0 | 0 |
| Withdrew: Adverse event | 19 | 23 | 0 | 0 |
| Withdrew: Disease progression | 14 | 26 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 17 | 0 | 0 |
| Withdrew: Death | 3 | 6 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 1 | 0 | 0 |
| Milestone | pNET (Core) | Non-pNET (Core) | Lung NET (E1) | GI NET (E1) |
|---|---|---|---|---|
| Started | 0 | 0 | 4 | 11 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 4 | 11 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 1 |
| Withdrew: Patients completed per protocol | 0 | 0 | 0 | 2 |
| Withdrew: Disease progression | 0 | 0 | 4 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
The number of participants with AEs, SAEs and deaths were assessed.
| Participants | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Adverse events | 90 | 109 |
| Serious adverse events | 25 | 59 |
| Deaths | 5 | 10 |
The number of participants with AEs, SAEs and deaths were assessed.
| Participants | Lung NET (E1) | GI NET |
|---|---|---|
| AEs | 4 | 11 |
| SAEs | 1 | 4 |
| Deaths | 0 | 1 |
PFS was defined as the time from the date of the first dose to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the study end date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last tumor assessment before the end of study date. Progression was defined,using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Months | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Investigator-assessed Progression Free Survival (PFS) (Core) | 7.62 (5.52 to 7.62) | 10.78 (8.77 to NA) |
The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.
| units on a scale | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Global health status/QOL, Baseline | 64.93 ± 20.946 | 60.53 ± 21.497 |
| Global health status/QOL, Week 4 | 63.15 ± 19.673 | 58.91 ± 20.622 |
| Global health status/QOL, Week 8 | 59.72 ± 21.303 | 56.59 ± 20.417 |
| Global health status/QOL,Week 20 | 63.10 ± 22.387 | 59.65 ± 17.663 |
| Global health status/QOL, Week 32 | 50.0 ± 26.352 | 56.20 ± 20.297 |
| Global health status/QOL, Week 44 | 61.11 ± 9.623 | 57.74 ± 25.205 |
| Global health status/QOL, EOT up to Week 82 | 61.40 ± 20.847 | 48.86 ± 27.823 |
| Physical functioning, Baseline | 79.89 ± 20.850 | 72.97 ± 22.938 |
| Physical functioning, week 4 | 77.02 ± 22.380 | 68.62 ± 23.648 |
| Physical functioning, week 8 | 76.22 ± 25.810 | 67.48 ± 24.973 |
| Physical functioning, week 20 | 79.77 ± 18.212 | 73.71 ± 21.351 |
| Physical functioning, week 32 | 68.00 ± 26.415 | 71.62 ± 23.729 |
| Physical functioning, week 44 | 68.89 ± 13.878 | 76.19 ± 22.602 |
| Physical functioning, EOT up to week 82 | 75.70 ± 24.509 | 60.94 ± 28.037 |
| Role functioning, Baseline | 75.28 ± 28.663 | 67.27 ± 32.397 |
| Role functioning, week 4 | 72.49 ± 28.364 | 62.25 ± 30.483 |
| Role functioning, week 8 | 71.83 ± 30.025 | 58.14 ± 31.460 |
| Role functioning, week 20 | 79.76 ± 25.803 | 58.33 ± 29.129 |
| Role functioning, week 32 | 66.67 ± 26.352 | 55.26 ± 35.325 |
| Role functioning, week 44 | 61.11 ± 9.623 | 66.67 ± 26.954 |
| Role functioning, EOT up to week 82 | 67.84 ± 31.788 | 49.13 ± 33.212 |
| Emotional functioning, Baseline | 74.79 ± 22.650 | 67.20 ± 22.988 |
| Emotional functioning, week 4 | 76.31 ± 20.991 | 66.69 ± 25.380 |
| Emotional functioning, week 8 | 73.38 ± 24.730 | 64.02 ± 26.640 |
| Emotional functioning, week 20 | 76.19 ± 19.072 | 63.16 ± 27.456 |
| Emotional functioning, week 32 | 81.67 ± 14.907 | 61.11 ± 28.184 |
| Emotional functioning, week 44 | 75.00 ± 8.333 | 65.67 ± 31.059 |
| Emotional functioning, EOT up to week 82 | 74.61 ± 23.602 | 57.63 ± 25.841 |
| Cognitive functioning, Baseline | 84.17 ± 19.630 | 80.61 ± 23.842 |
| Cognitive functioning, week 4 | 86.11 ± 20.050 | 78.80 ± 23.708 |
| Cognitive functioning, week 8 | 81.94 ± 21.803 | 76.33 ± 27.418 |
| Cognitive functioning, week 20 | 83.93 ± 19.501 | 78.65 ± 23.307 |
| Cognitive functioning, week 32 | 86.67 ± 18.257 | 75.21 ± 24.445 |
| Cognitive functioning, week 44 | 94.44 ± 9.623 | 84.52 ± 20.111 |
| Cognitive functioning, EOT up to week 82 | 81.35 ± 21.241 | 73.46 ± 24.522 |
| Social functioning, Baseline | 75.56 ± 28.249 | 67.42 ± 28.989 |
| Social functioning, week 4 | 78.71 ± 23.347 | 67.80 ± 30.093 |
| Social functioning, week 8 | 75.69 ± 24.695 | 65.31 ± 29.396 |
| Social functioning, week 20 | 73.21 ± 24.148 | 66.07 ± 29.977 |
| Social functioning, week 32 | 60.00 ± 27.889 | 66.24 ± 32.329 |
| Social functioning, week 44 | 66.67 ± 0.000 | 72.62 ± 31.082 |
| Social functioning, EOT up to week 82 | 75.10 ± 27.533 | 52.89 ± 33.933 |
| Fatigue, baseline | 31.30 ± 22.361 | 42.39 ± 28.534 |
| Fatigue, week 4 | 35.22 ± 22.887 | 43.58 ± 28.035 |
| Fatigue, week 8 | 36.91 ± 25.515 | 48.86 ± 29.878 |
| Fatigue, week 20 | 34.29 ± 18.430 | 44.44 ± 27.698 |
| Fatigue, week 32 | 42.22 ± 18.257 | 48.72 ± 29.575 |
| Fatigue, week 44 | 37.04 ± 6.415 | 38.89 ± 26.777 |
| Fatigue, EOT up to week 82 | 38.83 ± 24.896 | 56.49 ± 30.474 |
| Nausea and vomiting, Baseline | 11.25 ± 17.442 | 9.46 ± 17.353 |
| Nausea and vomiting, week 4 | 10.52 ± 15.998 | 7.43 ± 14.995 |
| Nausea and vomiting, week 8 | 9.59 ± 17.984 | 10.34 ± 18.015 |
| Nausea and vomiting, week 20 | 8.05 ± 15.185 | 6.14 ± 12.048 |
| Nausea and vomiting, week 32 | 6.67 ± 9.129 | 5.98 ± 11.139 |
| Nausea and vomiting, week 44 | 11.11 ± 9.623 | 4.76 ± 10.187 |
| Nausea and vomiting, EOT up to week 82 | 9.69 ± 17.048 | 15.80 ± 27.023 |
| Pain, Baseline | 21.57 ± 24.582 | 31.21 ± 31.535 |
| Pain, week 4 | 25.91 ± 26.716 | 30.88 ± 29.796 |
| Pain, week 8 | 25.23 ± 27.972 | 37.55 ± 32.372 |
| Pain, week 20 | 27.98 ± 22.247 | 33.33 ± 32.581 |
| Pain, week 32 | 43.33 ± 27.889 | 34.62 ± 32.977 |
| Pain, week 44 | 38.89 ± 9.623 | 26.19 ± 30.462 |
| Pain, EOT up to week 82 | 27.33 ± 28.343 | 43.90 ± 33.362 |
| Dyspnea, Baseline | 16.11 ± 22.448 | 24.32 ± 29.110 |
| Dyspnea, week 4 | 17.80 ± 24.171 | 26.14 ± 28.388 |
| Dyspnea, week 8 | 21.00 ± 27.502 | 29.12 ± 31.665 |
| Dyspnea, week 20 | 11.49 ± 18.422 | 28.07 ± 30.072 |
| Dyspnea, week 32 | 13.33 ± 18.257 | 35.90 ± 31.885 |
| Dyspnea, week 44 | 22.22 ± 19.245 | 21.43 ± 28.063 |
| Dyspnea, EOT up to week 82 | 25.19 ± 30.222 | 33.77 ± 30.824 |
| Insomnia, Baseline | 24.72 ± 30.093 | 28.18 ± 32.929 |
| Insomnia, week 4 | 27.78 ± 29.324 | 32.36 ± 30.769 |
| Insomnia, week 8 | 32.88 ± 30.171 | 29.02 ± 28.540 |
| Insomnia, week 24 | 24.14 ± 26.572 | 35.09 ± 32.380 |
| Insomnia, week 32 | 26.67 ± 27.889 | 33.33 ± 32.880 |
| Insomnia, week 48 | 22.22 ± 19.245 | 28.57 ± 36.648 |
| Insomnia, EOT up o week 82 | 32.17 ± 31.289 | 34.63 ± 32.643 |
| Appetite loss, Baseline | 20.56 ± 30.613 | 18.62 ± 29.365 |
| Appetitie loss, week 4 | 25.16 ± 31.618 | 21.90 ± 29.849 |
| Appetitie loss, week 8 | 24.66 ± 30.946 | 25.67 ± 31.623 |
| Appetitie loss, week 24 | 18.39 ± 27.583 | 20.47 ± 27.998 |
| Appetitie loss, week 36 | 20.00 ± 18.257 | 23.93 ± 30.540 |
| Appetitie loss, week 44 | 11.11 ± 19.245 | 26.19 ± 29.753 |
| Appetitie loss, EOT up to week 82 | 24.14 ± 29.505 | 33.77 ± 37.906 |
| Constipation, Baseline | 13.06 ± 24.175 | 13.21 ± 27.072 |
| Constipation, week 4 | 11.00 ± 24.427 | 11.33 ± 24.501 |
| Constipation, week 8 | 10.50 ± 24.137 | 7.58 ± 22.447 |
| Constipation, week 20 | 6.90 ± 16.377 | 8.77 ± 21.387 |
| Constipation, week 32 | 0.00 ± 0.000 | 4.27 ± 13.636 |
| Constipation, week 44 | 0.00 ± 0.000 | 2.38 ± 8.909 |
| Constipation, EOT up to week 82 | 12.79 ± 24.611 | 10.39 ± 23.107 |
| Diarrhea, Baseline | 19.89 ± 29.535 | 36.67 ± 38.828 |
| Diarrhea, week 4 | 20.92 ± 25.658 | 38.19 ± 36.577 |
| Diarrhea, week 8 | 27.40 ± 29.576 | 42.42 ± 39.708 |
| Diarrhea, week 20 | 16.67 ± 21.276 | 31.58 ± 29.828 |
| Diarrhea, week 32 | 13.33 ± 18.257 | 40.17 ± 36.015 |
| Diarrhea, week 44 | 22.22 ± 19.245 | 40.48 ± 37.390 |
| Diarrhea, EOT up to week 82 | 25.97 ± 32.095 | 39.04 ± 38.639 |
| Financial difficulties, Baseline | 18.77 ± 26.975 | 16.52 ± 25.770 |
| Financial difficulties, week 4 | 16.67 ± 24.845 | 16.67 ± 27.010 |
| Financial difficulties, week 8 | 19.44 ± 26.091 | 16.86 ± 24.837 |
| Financial difficulties, week 20 | 21.43 ± 22.616 | 19.88 ± 27.357 |
| Financial difficulties, week 32 | 40.00 ± 27.889 | 21.37 ± 28.084 |
| Financial difficulties, week 44 | 22.22 ± 19.245 | 19.05 ± 25.198 |
| Financial difficulties, EOT up to week 82 | 21.71 ± 27.897 | 27.63 ± 30.496 |
The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions and disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening.
| units on a scale | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Endocrine, Baseline | 12.99 ± 20.372 | 23.52 ± 23.771 |
| Endocrine, week 4 | 13.21 ± 17.440 | 17.85 ± 21.403 |
| Endocrine, week 8 | 13.47 ± 17.293 | 16.79 ± 20.216 |
| Endocrine, week 20 | 12.50 ± 12.511 | 15.87 ± 21.067 |
| Endocrine, week 32 | 16.67 ± 14.344 | 13.74 ± 17.978 |
| Endocrine, week 44 | 0.00 ± NA | 7.14 ± 11.202 |
| Endocrine, EOT up to week 82 | 9.49 ± 15.627 | 15.20 ± 18.755 |
| G.I., Baseline | 23.69 ± 20.183 | 26.19 ± 21.328 |
| G.I., week 4 | 23.02 ± 20.488 | 23.39 ± 18.958 |
| G.I., week 8 | 22.34 ± 18.398 | 27.53 ± 21.341 |
| G.I., week 20 | 25.63 ± 14.056 | 22.31 ± 18.837 |
| G.I., week 32 | 25.00 ± 11.386 | 26.84 ± 19.879 |
| G.I., week 44 | 0.00 ± NA | 20.95 ± 16.714 |
| G.I., EOT up to week 82 | 25.85 ± 19.899 | 30.48 ± 24.484 |
| Treatment, baseline | 9.26 ± 11.675 | 18.44 ± 19.374 |
| Treatment, week 4 | 17.72 ± 15.337 | 22.22 ± 20.077 |
| Treatment, week 8 | 16.18 ± 19.528 | 20.27 ± 17.283 |
| Treatment, week 20 | 28.70 ± 21.493 | 19.74 ± 19.755 |
| Treatment, week 32 | 27.78 ± 7.857 | 24.49 ± 23.684 |
| Treatment, week 44 | 16.67 ± NA | 18.18 ± 18.936 |
| Treatment, EOT up to week 82 | 22.06 ± 21.705 | 24.81 ± 21.735 |
| Social function, Baseline | 39.56 ± 23.721 | 47.42 ± 25.726 |
| Social function, week 4 | 36.52 ± 26.294 | 45.28 ± 27.483 |
| Social function, week 8 | 38.35 ± 23.629 | 46.49 ± 26.265 |
| Social function, week 20 | 40.28 ± 14.472 | 42.66 ± 25.648 |
| Social function, week 32 | 38.89 ± 14.344 | 48.54 ± 23.735 |
| Social function, week 44 | 33.33 ± NA | 40.08 ± 26.165 |
| Social function, EOT up to week 82 | 38.89 ± 25.051 | 54.22 ± 28.428 |
| Disease-related worries, Baseline | 43.10 ± 25.599 | 53.94 ± 27.664 |
| Disease-related worries, week 4 | 39.20 ± 28.562 | 46.33 ± 28.165 |
| Disease-related worries, week 8 | 40.56 ± 28.183 | 47.32 ± 28.541 |
| Disease-related worries, week 20 | 37.50 ± 8.267 | 46.83 ± 32.096 |
| Disease-related worries, week 32 | 38.89 ± 11.111 | 53.51 ± 27.137 |
| Disease-related worries, week 44 | 33.33 ± NA | 44.05 ± 32.647 |
| Disease-related worries, EOT up to week 82 | 42.89 ± 28.876 | 55.04 ± 31.667 |
| Muscle/bone pain, Baseline | 26.67 ± 33.347 | 29.66 ± 31.210 |
| Muscle/bone pain, week 4 | 24.07 ± 29.966 | 33.00 ± 31.956 |
| Muscle/bone pain, week 8 | 31.18 ± 34.357 | 33.33 ± 33.524 |
| Muscle/bone pain, week 20 | 41.67 ± 15.430 | 34.52 ± 33.614 |
| Muscle/bone pain, week 32 | 50.00 ± 19.245 | 40.35 ± 34.795 |
| Muscle/bone pain, week 44 | 33.33 ± NA | 26.19 ± 26.726 |
| Muscle/bone pain, EOT up to week 82 | 34.13 ± 28.973 | 40.89 ± 33.141 |
| Sexual function, Baseline | 35.46 ± 32.899 | 39.32 ± 40.468 |
| Sexual function, week 4 | 21.05 ± 26.191 | 40.89 ± 40.483 |
| Sexual function, week 8 | 28.79 ± 33.007 | 43.92 ± 40.083 |
| Sexual function, week 20 | 33.33 ± 33.333 | 38.10 ± 39.724 |
| Sexual function, week 32 | 11.11 ± 19.245 | 29.17 ± 35.864 |
| Sexual function, week 44 | — | 47.62 ± 46.576 |
| Sexual function, EOT up to week 82 | 25.81 ± 28.166 | 48.94 ± 43.323 |
| Communication function, Baseline | 7.58 ± 16.325 | 9.88 ± 22.904 |
| Communication function, week 4 | 8.18 ± 17.179 | 6.46 ± 15.626 |
| Communication function, week 8 | 12.22 ± 18.535 | 9.69 ± 19.714 |
| Communication function, week 20 | 14.29 ± 17.817 | 10.30 ± 19.108 |
| Communication function, week 32 | 8.33 ± 16.667 | 7.89 ± 19.658 |
| Communication function, week 44 | 0.00 ± NA | 4.76 ± 12.105 |
| Communication function, EOT up to week 82 | 12.70 ± 22.028 | 12.61 ± 23.214 |
| Body image, Baseline | 15.90 ± 28.932 | 22.43 ± 34.195 |
| Body image, week 4 | 15.09 ± 27.399 | 22.79 ± 31.239 |
| Body image, week 8 | 21.51 ± 27.953 | 26.10 ± 31.256 |
| Body image, week 20 | 16.67 ± 17.817 | 30.30 ± 34.708 |
| Body image, week 32 | 0.00 ± 0.000 | 28.83 ± 33.483 |
| Body image, week 44 | 0.00 ± NA | 30.95 ± 27.625 |
| Body image, EOT up to week 82 | 23.02 ± 32.500 | 34.70 ± 37.449 |
The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.
| Participants | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Baseline, Mobility, No problem | 84 | 76 |
| Baseline, Mobility, Some problem | 31 | 35 |
| Baseline, Mobility, Extreme problem | 2 | 1 |
| Baseline, Self-care, No problem | 100 | 102 |
| Baseline, Self-care, Some problem | 15 | 10 |
| Baseline, Self-care, Extreme problem | 2 | — |
| Baseline, Usual activities, No problem | 71 | 60 |
| Baseline, Usual activities, Some problem | 43 | 46 |
| Baseline, Usual actvities, Extreme problem | 4 | 6 |
| Baseline, Pain/Discomfort, No problem | 59 | 40 |
| Baseline, Pain/discomfort, Some problem | 52 | 66 |
| Baseline, Pain/discomfort, Extreme problem | 6 | 7 |
| Baseline, Anxiety/depression, No problem | 65 | 53 |
| Baseline, Anxiety/depression, Some problem | 47 | 54 |
| Baseline, Anxiety/depression, Extreme problem | 5 | 6 |
| Week 4, Mobility, No problem | 72 | 66 |
| Week 4, Mobility, Some problem | 27 | 37 |
| Week 4, Mobility, Extreme problem | 2 | 1 |
| Week 4, Self-care, No problem | 89 | 86 |
| Week 4, Self-care, Some problem | 10 | 16 |
| Week 4, Self-care, Extreme problem | 3 | 2 |
| Week 4, Usual activities, No problem | 66 | 55 |
| Week 4, Usual activities, Some problem | 31 | 42 |
| Week 4, Usual activities, Extreme problem | 4 | 7 |
| Week 4, Pain/discomfort, No problem | 39 | 30 |
| Week 4, Pain/discomfort, Some problem | 58 | 64 |
| Week 4, Pain/discomfort, Extreme problem | 3 | 8 |
| Week 4, Anxiety/depression, No problem | 54 | 57 |
| Week 4, Anxiety depression, Some problem | 46 | 43 |
| Week 4, Anxiety/depression, Extreme problem | 1 | 3 |
| Week 8, Mobility, No problem | 48 | 45 |
| Week 8, Mobility, Some problem | 24 | 37 |
| Week 8, Mobility, Extreme problem | 2 | 3 |
| Week 8, Self-care, No problem | 61 | 70 |
| Week 8, Self-care, Some problem | 7 | 15 |
| Week 8, Self-care, Extreme problem | 6 | 1 |
| Week 8, Usual activities, No problem | 46 | 40 |
| Week 8, Usual activities, Some problem | 23 | 41 |
| Week 8, Usual activties, Extreme problem | 4 | 5 |
| Week 8, Pain/discomfort, No problem | 34 | 25 |
| Week 8, Pain/discomfort, Some problem | 32 | 52 |
| Week 8, Pain/discomfort, Extreme problem | 7 | 10 |
| Week 8, Anxiety/depression, No problem | 43 | 38 |
| Week 8, Anxiety/depression, Some problem | 30 | 41 |
| Week 8, Anxiety/depression, Extreme problem | 1 | 8 |
| Week 20, Mobility, No problem | 26 | 37 |
| Week 20, Mobility, Some problem | 3 | 17 |
| Week 20, Mobility, Extreme problem | — | 1 |
| Week 20, Self-care, No problem | 25 | 49 |
| Week 20, Self-care, Some problem | 4 | 6 |
| Week 20, Usual activities, No problem | 18 | 30 |
| Week 20 Usual activities, Some problem | 10 | 22 |
| Week 20, Usual activities, Extreme problem | 1 | 2 |
| Week 20, Pain/discomfort, No problem | 12 | 19 |
| Week 20, Pain/discomfort, Some problem | 16 | 34 |
| Week 20, Pain/discomfort, Extreme problem | 1 | 2 |
| Week 20, Anxiety/depression, No problem | 16 | 27 |
| Week 20, Anxiety/depression, Some problem | 12 | 23 |
| Week 20, Anxiety/depression, Extreme problem | 1 | 5 |
| Week 32, Mobility, No problem | 3 | 25 |
| Week 32, Mobility, Some problem | 2 | 12 |
| Week 32, Mobility, Extreme problem | — | 2 |
| Week 32, Self-care, No problem | 5 | 32 |
| Week 32, Self-care, Some problem | — | 3 |
| Week 32, Self-care, Extreme problem | — | 2 |
| Week 32, Usual activities, No problem | 4 | 22 |
| Week 32, Usual activities, Some problem | 1 | 14 |
| Week 32, Usual activities, Extreme problem | — | 3 |
| Week 32, Pain/discomfort, No problem | 1 | 10 |
| Week 32, Pain/discomfort, Some problem | 4 | 27 |
| Week 32, Pain/discomfort, Extreme problem | — | 2 |
| Week 32, Anxiety/depression, No problem | 4 | 20 |
| Week 32, Anxiety/depression, Some problem | 1 | 14 |
| Week 32, Anxiety/depression, Extreme problem | — | 5 |
| Week 44, Mobility, No problem | 2 | 9 |
| Week 44, Mobility, Some problem | 1 | 4 |
| Week 44, Mobility, Extreme problem | — | 1 |
| Week 44, Self-care, No problem | 3 | 12 |
| Week 44, Self-care, Some problem | — | 2 |
| Week 44, Usual activities, No problem | — | 6 |
| Week 44, usual activities, Some problem | 3 | 7 |
| Week 44, Pain/discomfort, No problem | — | 6 |
| Week 44, Pain/discomfort, Some problem | 3 | 8 |
| Week 44, Anxiry/depression, No problem | 1 | 7 |
| Week 44, Anxiety/depression, Some problem | 2 | 6 |
| Week 44, Anxiety/depression, Extreme problem | — | 1 |
| EOT up to Week 82, Mobility, No problem | 59 | 42 |
| EOT up to Week 82, Mobility, Some problem | 23 | 31 |
| EOT up to Week 82, Mobility, Extreme problem | 4 | 4 |
| EOT up to Week 82, Self-care, No problem | 69 | 56 |
| EOT up to Week 82, Self-care, Some problem | 12 | 19 |
| EOT up to Week 82, Self-care, Extreme problem | 2 | 1 |
| EOT up toWeek 82, Usual activities, No problem | 54 | 29 |
| EOT up to Week 82, Usual activities, Some problem | 24 | 36 |
| EOT up to Week 82, Usual activities, Extreme prob. | 5 | 11 |
| EOT up to Week 82, Pain/discomfort, No problem | 43 | 18 |
| EOT up to Week 82, Pain/discomfort, Some problem | 36 | 48 |
| EOT up to Week 82, Pain/discomfort, Extreme prob. | 5 | 11 |
| EOT up to Week 82, Anxiety/depression, No problem | 48 | 31 |
| EOT up to Week 82, Anxiety/depression, Some prob. | 33 | 40 |
| EOT up toWeek 82, Anxiety/depression, Extreme prob | 3 | 6 |
The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.
| units on a scale | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Baseline | 68.8 ± 19.90 | 63.9 ± 19.09 |
| Week 4 | 69.3 ± 18.06 | 63.8 ± 18.78 |
| Week 8 | 64.6 ± 21.77 | 61.2 ± 18.65 |
| Week 20 | 67.4 ± 19.58 | 64.6 ± 15.51 |
| Week 32 | 42.6 ± 24.67 | 62.0 ± 17.65 |
| Week 44 | 66.7 ± 15.28 | 68.6 ± 18.71 |
| EOT up to Week 82 | 66.5 ± 20.64 | 55.3 ± 23.02 |
Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Participants | pNET (Core) | Non-pNET (Core) |
|---|---|---|
| Partial response (PR) | 2 | 1 |
| Stable disease (SD) | 74 | 84 |
| Progressive disease (PD) | 9 | 8 |
| Unknown | 41 | 27 |
| Objective response rate (complete response or PR) | 2 | 1 |
PFS was defined as the time from the date of the start of therapy in the extension study to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the analysis cut-off date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last adequate tumor evaluation before the cut-off date or the anti-neoplastic therapy start date.
| Days | Lung NET (E1) | GI NET (E1) |
|---|---|---|
| Investigator-assessed Progression Free Survival (PFS) (E1) | 159 (10 to 1074) | 655 (9 to NA) |
The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status and QOL scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status and QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, changes are calculated as value at later time point minus value at baseline, and final scores are transformed such that they range from 0-100, where higher scores indicate better outcomes. A positive change from baseline indicates improvement.
| score on a scale | Lung NET (E1) | GI NET |
|---|---|---|
| Global health status/QoL | 0.00 ± NA | -0.00 ± 11.785 |
| Functional scale: Physical functioning | 6.67 ± NA | 0.00 ± 7.303 |
| Functional scale: Role functioning | -16.67 ± NA | 5.56 ± 22.771 |
| Functional scale: Emotional functioning | -25.00 ± NA | -1.85 ± 17.003 |
| Functional scale: Cognitive functioning | -66.67 ± NA | -16.67 ± 21.082 |
| Functional scale: Social functioning | 0.00 ± NA | -8.33 ± 9.129 |
| Symptom scale: Fatigue | 0.00 ± NA | -3.70 ± 22.951 |
| Symptom scale: Nausea and vomiting | 0.00 ± NA | 0.00 ± 18.257 |
| Symptom scale: Pain | 0.00 ± NA | 16.67 ± 27.889 |
| Symptom scale: Dyspnea | 0.00 ± NA | -5.56 ± 13.608 |
| Symptom scale: Insomnia | 33.33 ± NA | 11.11 ± 17.213 |
| Symptom scale: Appetite loss | 0.00 ± NA | 0.00 ± 21.082 |
| Symptom scale: Constipation | 0.00 ± NA | 5.56 ± 25.092 |
| Symptom scale: Diarrhea | 0.00 ± NA | -16.67 ± 45.947 |
| Symptom scale: Financial difficulties | -33.33 ± NA | 16.67 ± 18.257 |
The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions, disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening outcomes. A positive change from baseline indicates worsening.
| units on a scale | Lung NET (E1) | GI NET |
|---|---|---|
| Social function | 11.11 ± NA | 7.41 ± 22.951 |
| Disease-related worries | 44.44 ± NA | -0.93 ± 7.384 |
| Sexual function | — | 50.00 ± 43.033 |
| Communicative functioning | 0.00 ± NA | 11.11 ± 17.213 |
| Endocrine scale | 11.11 ± NA | 5.56 ± 18.257 |
| G.I. scale | 0.00 ± NA | 14.44 ± 23.633 |
| Treatment scale | -16.67 ± NA | 5.56 ± 12.423 |
| Muscle/bone pain symptom | — | 33.33 ± 29.814 |
| Body image | 0.00 ± NA | 0.00 ± 21.082 |
The EQ-5D contains 2 sections:1st section has 1 item addressing each of 5 dimensions (mobility, self-care, usual activity, pain/discomfort, anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems, 1-3, respectively. A health state is defined by combining 1 level from each dimension. 243 health states are possible. Each state is referred to in a 5 digit code. E.g., state 11111 indicates no problems on any dimension, while state 11223 indicates no problems with mobility and self-care, some problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression. The 2nd section measures self-rated health status using a visual analogue scale (VAS) where 100 represents best possible health and 0 represents worst possible health. Patients are asked to rate their current health by placing a mark on the VAS. Scores from each section are then transformed into an overall score of 0 or 1, with 0= higher level of dysfunction.
| units on a scale | Lung NET (E1) | GI NET |
|---|---|---|
| Composite health index | 7.26 ± NA | -8.58 ± 13.302 |
| Self-rated health status | -10.00 ± NA | -4.17 ± 21.479 |
Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Participants | Lung NET (E1) | GI NET |
|---|---|---|
| Complete response | 0 | 0 |
| Partial response | 0 | 1 |
| Stable disease | 2 | 7 |
| Progressive disease | 2 | 3 |
| Unknown | 0 | 0 |
Collected over up to 19 month for the core and up to 4 years for the extension. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| pNET (Core) | — | 25/123 (20.3%) | 73/123 (59.3%) |
| Non-pNET (Core) | — | 59/117 (50.4%) | 89/117 (76.1%) |
| Lung NET (E1) | — | 1/4 (25%) | 4/4 (100%) |
| GI NET (E1) | — | 4/11 (36.4%) | 11/11 (100%) |
| Event | pNET (Core) | Non-pNET (Core) | Lung NET (E1) | GI NET (E1) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/123 | 3/117 | 1/4 | 0/11 |
| Cardiac failureCardiac disorders | 1/123 | 2/117 | 1/4 | 0/11 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/123 | 1/117 | 1/4 | 0/11 |
| Retinal vascular thrombosisEye disorders | 0/123 | 0/117 | 0/4 | 1/11 |
| Abdominal herniaGastrointestinal disorders | 0/123 | 0/117 | 0/4 | 1/11 |
| Abdominal painGastrointestinal disorders | 1/123 | 5/117 | 0/4 | 1/11 |
| ConstipationGastrointestinal disorders | 0/123 | 0/117 | 0/4 | 1/11 |
| Inguinal herniaGastrointestinal disorders | 0/123 | 0/117 | 0/4 | 1/11 |
| DeathGeneral disorders | 0/123 | 0/117 | 0/4 | 1/11 |
| General physical health deteriorationGeneral disorders | 2/123 | 7/117 | 0/4 | 1/11 |
| Event | pNET (Core) | Non-pNET (Core) | Lung NET (E1) | GI NET (E1) |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/123 | 4/117 | 2/4 | 1/11 |
| FlatulenceGastrointestinal disorders | 0/123 | 1/117 | 2/4 | 3/11 |
| BronchitisInfections and infestations | 1/123 | 2/117 | 2/4 | 0/11 |
| NasopharyngitisInfections and infestations | 2/123 | 5/117 | 2/4 | 5/11 |
| Abdominal painGastrointestinal disorders | 4/123 | 10/117 | 0/4 | 5/11 |
| HypertensionVascular disorders | 5/123 | 6/117 | 0/4 | 5/11 |
| Oedema peripheralGeneral disorders | 5/123 | 15/117 | 0/4 | 4/11 |
| Back painMusculoskeletal and connective tissue disorders | 0/123 | 6/117 | 0/4 | 4/11 |
| DiarrhoeaGastrointestinal disorders | 10/123 | 34/117 | 0/4 | 3/11 |
| AnaemiaBlood and lymphatic system disorders | 7/123 | 10/117 | 1/4 | 3/11 |
| Age, Continuous(years) | pNET (Core) | Non-pNET (Core) | Total |
|---|---|---|---|
| Mean | 59.3 ± 13.04 | 64.4 ± 9.28 | 61.8 ± 11.62 |
| Sex: Female, Male(Participants) | pNET (Core) | Non-pNET (Core) | Total |
|---|---|---|---|
| Female | 58 | 61 | 119 |
| Male | 68 | 59 | 127 |
The record gives a start of Apr 2011, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus